Promoters of Eris Lifesciences Limited have confirmed that they hold 7,47,08,744 equity shares, representing approximately 53.92% of the total shareholding as on March 31, 2026. In a declaration submitted to the stock exchanges, the promoters stated that there are no encumbrances on these shares, directly or indirectly, other than those already disclosed during the financial year. This disclosure ensures shareholders that the promoter group's significant stake remains unpledged, providing stability to the company's ownership structure.

The declaration was made by Kaushal Kamlesh Shah on behalf of all Promoters and the Promoter Group pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was addressed to BSE Limited and National Stock Exchange of India Limited, as well as the Company Secretary of Eris Lifesciences Limited, to update official records.

Shareholding Details

The disclosure provides specific details regarding the promoter group's holding status for the financial year ended March 31, 2026.

The confirmation of a clean, unencumbered stake is significant for market participants, as it indicates that the promoters have not utilized their shares to raise funds, which could otherwise signal financial stress or liquidity requirements. The document was digitally signed by Kaushal Kamlesh Shah on April 06, 2026.

Eris Lifesciences Limited has informed the stock exchanges that the transcript of its Analyst and Investor call is now available. The call was held following the announcement of financial results for the quarter and year ended March 31, 2026. This disclosure allows stakeholders to access a detailed record of management's commentary on the company's performance for the period.

The communication was submitted to BSE Limited and National Stock Exchange of India Limited. The transcript provides a comprehensive review of the audited consolidated and standalone financial results discussed during the proceedings.

Conference Call Details

The session covered the financial performance of the company for the specified period. Investors and interested parties can review the management's analysis by accessing the document online.

Access Information

The transcript can be accessed via the following link on the company's website: https://eris.co.in/financials/ . The specific file name for the document is "Transcript of the Analyst and Investor Conference call Q4FY26".

The communication was signed by Milind Talegaonkar, Company Secretary and Compliance Officer of eris lifesciences .